Artelo Biosciences receives FDA clearance of IND application for ART26.12

Artelo Biosciences announced that the U.S. Food and Drug Administration, FDA, has issued a “Study May Proceed” letter for the Company’s Investigational New Drug, IND, application for ART26.12, for the treatment of chemotherapy-induced peripheral neuropathy, CIPN. FDA clearance of the ART26.12 IND application enables the Company to initiate its first-in-human Phase 1 single ascending dose study. “Receiving IND clearance validates our development efforts and underscores the potential impact of ART26.12 to improve patients’ lives,” said Gregory Gorgas, President and Chief Executive Officer of Artelo Biosciences. “We look forward to sharing the initial clinical results with ART26.12 next year. As the leading company pursuing FABP inhibiton we are committed to building on the unique, lipid-modulating mechanism of our FABP inhibitor platform to address life-altering pathologies for which there are few, if any, safe and effective pharmaceutical treatments.”